Long-chain testosterone ester and the most commonly prescribed form of testosterone replacement therapy in the United States. Oil-based injectable with an 8-day half-life.
Testosterone cypionate is a synthetic ester of testosterone attached to the cyclopentylpropionate (cypionate) carbon chain. The ester group slows the release of testosterone from the injection depot into the bloodstream, creating a sustained-release pharmacokinetic profile that allows for weekly or biweekly injection frequencies.
As the most widely prescribed testosterone formulation in the US, test cyp is the backbone of most TRT protocols. Its pharmacokinetic profile is very similar to testosterone enanthate, differing only by one additional carbon atom in the ester chain — which gives cypionate a marginally longer half-life (~8 days vs ~7 days for enanthate).
The compound is dissolved in a carrier oil (commonly cottonseed or grapeseed oil) at concentrations typically ranging from 100 mg/mL to 250 mg/mL. Once injected, the oil depot slowly releases the esterified testosterone, which is then cleaved by esterase enzymes to yield free testosterone.
After injection and ester hydrolysis, free testosterone binds to androgen receptors throughout the body. The androgen receptor is a nuclear receptor — once activated, it translocates to the nucleus and modulates gene expression. This is the same mechanism as endogenous testosterone; the cypionate ester simply controls the delivery timeline.
The cypionate ester is cleaved by nonspecific esterases in the blood and tissues, liberating bioidentical testosterone. The rate of ester hydrolysis — not the biological activity of testosterone itself — determines the pharmacokinetic profile. Longer ester chains produce slower hydrolysis and longer effective half-lives.
Testosterone cypionate follows a one-compartment pharmacokinetic model with first-order absorption from the injection depot and first-order elimination. The long ester chain creates a "flip-flop" kinetic profile where absorption is the rate-limiting step — meaning the apparent half-life is governed by the slow release from the oil depot rather than testosterone's intrinsic clearance rate.
| Parameter | Value |
|---|---|
| Terminal Half-Life | ~192 hours (8 days) |
| Time to Peak (Tmax) | ~48 hours post-injection |
| Bioavailability (IM) | ~95% |
| Total Duration of Action | ~504 hours (21 days) |
| Time to Steady State | ~5–6 weeks (with consistent dosing) |
| Peak-to-Trough Ratio (weekly) | ~1.5:1 |
| Peak-to-Trough Ratio (E3.5D) | ~1.25:1 |
Steady state occurs after approximately 5 half-lives of consistent dosing — roughly 5 to 6 weeks for testosterone cypionate. At this point, each injection maintains your blood concentration rather than continuing to build it. The peak-to-trough variation at steady state depends entirely on injection frequency: more frequent injections produce flatter, more stable levels.
Intramuscular injection delivers testosterone cypionate into highly vascularized muscle tissue, producing a relatively predictable absorption curve with peak levels around 48 hours post-injection. Subcutaneous injection places the oil depot in adipose tissue, where lower blood flow produces a slightly more gradual absorption profile. Many TRT protocols report similar total absorption with SubQ, but with a blunted peak and elevated trough — resulting in reduced peak-to-trough variation.
Dosing strategies for testosterone cypionate vary based on the context of use. The following represents commonly reported protocol structures:
Splitting a weekly dose into two injections (every 3.5 days) reduces the peak-to-trough ratio from approximately 1.5:1 to 1.25:1. This narrower fluctuation band is one of the primary reasons many TRT protocols favor twice-weekly dosing. Milligram models the exact concentration curve for any frequency you choose.